Mammoth Biosciences Company Overview
Mammoth Biosciences is a CRISPR-focused biotechnology company building tools for diagnostics and therapeutic genome editing. The company discovers and engineers compact CRISPR systems and enzymes, aiming to enable simpler delivery for in vivo editing and rapid, easy-to-use molecular testing. Its platform spans enzyme discovery, protein engineering, and assay design to support applications from point‑of‑care detection to genetic medicine. Mammoth partners with pharmaceutical, diagnostics, and technology firms to translate its CRISPR capabilities into products across multiple disease areas and testing settings. The company was co-founded by scientists including Jennifer Doudna, Trevor Martin, Janice Chen, and Lucas Harrington, and operates out of the San Francisco Bay Area.
New to Pre-IPO Investing?
Get smarter about private markets and Pre-IPO investing:
- Get key practice tips for private-market investing
- Understand how to evaluate deal terms and common structures
- Evaluate fees and their impact on returns
- Develop a thesis and underwrite your investment
- Learn common pitfalls first-time investors face
FAQ
Does Mammoth Biosciences have stock?
Yes, Mammoth Biosciences and almost all privately held companies issue stock so founders, employees, and investors can participate in equity ownership. However, because Mammoth Biosciences is privately held, it is more challenging to acquire shares than if the company was publicly traded.
Is Mammoth Biosciences publicly traded?
No, Mammoth Biosciences is a privately held company. It is not publicly traded or offered directly on any stock exchange like the NYSE, Nasdaq, etc.
Who owns Mammoth Biosciences stock?
As a privately held company, Mammoth Biosciences shares are held by its founders, management, employees, venture capital funds, or other private individuals and institutional investors.
Disclosure rules differ for private and public companies, so it may not always be possible to know the complete ownership (cap table) of a private company like Mammoth Biosciences.
What is the stock symbol for Mammoth Biosciences?
Mammoth Biosciences is a privately held company. Therefore, it does not have a stock symbol or “ticker” that trades on public exchanges like the NYSE, Nasdaq, etc.
Can I buy Mammoth Biosciences stock on UpMarket?
If you would like to buy shares in Mammoth Biosciences, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”
One of our investor relations team members will contact you to discuss Mammoth Biosciences stock availability. Note: inquiries are non-binding, subject to market availability, and shares may only be purchased by accredited investors that meet all eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, Mammoth Biosciences as well.
What is Mammoth Biosciences stock price?
The stock price of Mammoth Biosciences can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
How do Mammoth Biosciences pre-IPO trades work?
Pre-IPO trades for Mammoth Biosciences will typically involve accredited investors purchasing shares from current shareholders through specialized investment platforms like UpMarket. Trades generally occur on the secondary market, meaning Mammoth Biosciences doesn't issue new shares or receive capital–shares are privately exchanged between two parties.
While investors aim to profit from a potential IPO or acquisition, these investments carry high risks due to limited liquidity and information. Understanding all terms and conditions is crucial, as each transaction can have unique characteristics. Investing in private companies can be extremely risky and may result in significant capital loss.
When is Mammoth Biosciences going to go public?
The decision to go public through an Initial Public Offering (IPO) is complex and depends on various factors, including the company's financial performance, market conditions, and strategic goals.
Unless Mammoth Biosciences officially announces its intention to go public, any predictions about when or if it will do so would be speculative.
Investors interested in Mammoth Biosciences should monitor official company communications and reliable financial news sources for any updates regarding potential IPO plans.
How do I exit my investment if I invest in Mammoth Biosciences with UpMarket?
Exiting your investment in Mammoth Biosciences typically involves one of these scenarios: 1) selling your shares on a secondary market to other interested investors; 2) holding shares until a liquidity event occurs, such as the company going public (IPO) or being acquired.
Investors must know that the timing and availability of these exit options are inherently unpredictable, and there is no guarantee of when or if they will occur.
How can I sell Mammoth Biosciences shares?
If you own Mammoth Biosciences shares, you may be able to find a buyer on a pre-IPO marketplace or via an introduction by a registered broker-dealer like UpMarket. It is important to note that the class of shares you own may impact your ability to sell. For example, shares issued to startup employees often have transaction limitations, including lock-up periods and a right of first refusal by the company, which may prevent you from selling your shares freely.
How does UpMarket estimate the valuation of Mammoth Biosciences?
UpMarket’s valuation estimate for Mammoth Biosciences is algorithmically generated based on recent primary round financings by Mammoth Biosciences, market conditions, company popularity, sector performance, and public market comps.
It is important to note that UpMarket’s valuation estimate for Mammoth Biosciences could be outdated, may not reflect all recent news or market events, and is not intended to inform any investment decision-making. UpMarket’s valuation estimate is not meant to be a warranty or projection of potential financial returns or company performance. Valuations can change rapidly and unexpectedly.
Why choose UpMarket?
Founded in 2019, UpMarket has brokered over $450 million in alternative investments for more than 800 investors, including principal invested and appreciation as of May 31, 2025. These investments span pre-IPO companies, hedge funds, private equity, real estate, and other alternative assets. Approximately $92 million is managed by UpMarket Management, with the remainder managed by affiliates. Past performance is not predictive of future results. UpMarket is a licensed broker-dealer based in the United States.
If you are an accredited investor, you can create a free account to access our deal flow and opportunities. There is never any pressure to invest.
UpMarket clients have invested in companies like
Mammoth Biosciences,
SpaceX, Neuralink, Anthropic, and many others. UpMarket and its leadership have been mentioned in media outlets like Forbes, WealthManagement, Wealth and Finance News, and TechBullion.
Mammoth Biosciences Management
| Name | Position |
|---|---|
| Trevor Martin | CEO |
| Janice Chen | CTO |
| Lucas Harrington | CSO |
